

STENOCARE products are being used in clinical trials at Rigshospitalet Multiple Sclerosis Center

The Danish Programme for medical cannabis has objectives to both enable patients to be treated with cannabis, and to learn about the effects of the treatment via clinical trials.

According to the Danish Ministry of Health more than 1400 patients have been treated with medical cannabis during the last 14 mths – which is a higher number than expected by the Ministry.

Thomas Skovlund Schnegelsberg, CEO STENOCARE comments:

“The number of patients has grown months after months – as physicians prescribe medical cannabis as part of the treatment of pain, sclerosis and other illnesses. Denmark seem to follow similar patterns from countries like Germany and Canada with the gradual acceptance of this new treatment”.

During early 2019 Rigshospitalet started treatment and trails with medical cannabis. It is Rigshospitalet Muliple Sclerosis Center that is offering treatment that will capture clinical data from patients, and they will also seek to understand the aspects around dosage and effect. This will be important information for how to prescribe and define the right dosage protocols for patients. The STENOCARE medical cannabis oil products are being prescribed to the patients at the hospital.

Thomas Skovlund Schnegelsberg, CEO STENOCARE comments:

“As the number of treatments with medical cannabis increases – it is important that leading institutions like Rigshospitalet actively leverage the Danish Programme for medical cannabis. With their expertise and resources, they are vital for trial of this new type of treatment and for gathering knowledge of the effects with patients.”

There are also international trials with medical cannabis. Two examples of randomized, controlled, double-blind, placebo studies have been initiated by CannTrust and the McMaster University clinical trial for chronic pain and the Queensland Gold Coast University trial with slowing disease progression in Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND).

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot programme. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality medical cannabis oil, which is produced by hygienic and high technology cultivation that comply with the

Press release
March 20, 2019



strict Danish regulatory requirements. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company's premises in Jutland, Denmark